• Zhenrong Yan, Ziyang Xing, Tingyun Xue, Jiaye Zhao, Guangmei Li, Liwenjing Xu, and Qiyu Sun.
• Department of Clinical Laboratory, Affiliated Hospital of Chengde Medical University, Hebei, China.
• Medicine (Baltimore). 2024 Mar 1; 103 (9): e37279e37279.

AbstractMyocardial ischemia-reperfusion injury (MIRI) is a severe damage inflicted on the ischemic myocardium when blood flow is restored, and it commonly occurs in a wide range of cardiovascular diseases. Presently, no effective clinical treatment exists for MIRI. Accumulating evidence indicates that insulin-like growth factor-1 (IGF-1) plays a role in the intricate chain of cardiovascular events, in addition to its well-recognized growth-promoting and metabolic effects. IGF-1, a member of the insulin family, exhibits a broad spectrum of protective effects against ischemia/reperfusion injury in various tissues, especially the myocardium. In particular, earlier research has demonstrated that IGF-1 reduces cellular oxidative stress, improves mitochondrial function, interacts with noncoding RNAs, and activates cardiac downstream protective genes and protective signaling channels. This review aimed to summarize the role of IGF-1 in MIRI and elucidate its related mechanisms of action. In addition, IGF-1-related interventions for MIRI, such as ischemic preconditioning and post-conditioning, were discussed. The purpose of this review was to provide evidence supporting the activation of IGF-1 in MIRI and advocate its use as a therapeutic target.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…